What Repare Therapeutics Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 8 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 107,908 |
| Net activity | +0 | −107,908 |
Common stock only — 3 reported trades in the last 12 months are in a security these totals do not cover.
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Bvf Partners L P/IL | 10% owner | Jan 28 | Tender Offer · U | −548,938 | — | — | 0 |
| Bvf Partners L P/IL | 10% owner | Jan 28 | Tender Offer · U | −4,308,573 | — | — | 0 |
| Bvf Partners L P/IL | 10% owner | Jan 28 | Tender Offer · U | −5,309,432 | — | — | 0 |
| Schafer Carol | Director | Jan 28 | Disposition to Issuer · D | −8,000 | — | — | 0 |
| Forte Steve | EVP, CHIEF FINANCIAL OFFICER | Jan 28 | Disposition to Issuer · D | −56,786 | — | — | 0 |
| Alves Sandra Isabelle Barros | SVP, Finance and CAO | Jan 28 | Disposition to Issuer · D | −31,622 | — | — | 0 |
| Rhoads Ann D | Director | Jan 28 | Disposition to Issuer · D | −4,000 | — | — | 0 |
| Civik Thomas | Director | Jan 28 | Disposition to Issuer · D | −7,500 | — | — | 0 |
| Alves Sandra Isabelle Barros | SVP, Finance and CAO | Apr 02 | Grant / award · A | +4,100 | — | — | 29,622 |
| Segal Lloyd Mitchell | PRESIDENT AND CEO | Mar 12 | Open-market sale · S | −21,179 | $1.14 | −$24.1K | 124,394 |
| Forte Steve | EVP, CHIEF FINANCIAL OFFICER | Mar 12 | Open-market sale · S | −6,884 | $1.14 | −$7.85K | 54,786 |
| Koehler Maria | EVP, CHIEF MEDICAL OFFICER | Mar 12 | Open-market sale · S | −3,596 | $1.14 | −$4.1K | 227,813 |
| Zinda Michael | EVP, CHIEF SCIENTIFIC OFFICER | Mar 12 | Open-market sale · S | −5,611 | $1.14 | −$6.4K | 80,297 |
| Segal Lloyd Mitchell | PRESIDENT AND CEO | Mar 04 | Grant / award · A | +40,000 | — | — | 145,573 |
| Forte Steve | EVP, CHIEF FINANCIAL OFFICER | Mar 04 | Grant / award · A | +14,000 | — | — | 61,670 |
| Zinda Michael | EVP, CHIEF SCIENTIFIC OFFICER | Mar 04 | Grant / award · A | +14,000 | — | — | 85,908 |
| Segal Lloyd Mitchell | PRESIDENT AND CEO | Apr 01 | Open-market sale · S | −2,491 | $4.63 | −$11.5K | 107,558 |
| Forte Steve | EVP, CHIEF FINANCIAL OFFICER | Apr 01 | Open-market sale · S | −789 | $4.61 | −$3.64K | 44,775 |
| Koehler Maria | EVP, CHIEF MEDICAL OFFICER | Apr 01 | Open-market sale · S | −300 | $4.66 | −$1.4K | 231,409 |
| Zinda Michael | EVP, CHIEF SCIENTIFIC OFFICER | Apr 01 | Open-market sale · S | −410 | $4.66 | −$1.91K | 71,908 |
Loading...
